NCT02075073View on ClinicalTrials.gov

Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Healthy
Interventions
BIOLOGICAL

SB3

BIOLOGICAL

EU sourced Herceptin®

BIOLOGICAL

US sourced Herceptin®

Trial Locations (1)

Unknown

Samsung Investigational Site, Berlin

All Listed Sponsors
lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT02075073 - Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter